Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00390
|
|||||
| Drug Name |
Fluvoxamine
|
|||||
| Synonyms |
(1E)-5-methoxy-1-[4-(trifluoromethyl)phenyl]pentan-1-one O-(2-aminoethyl)oxime; 2-[(E)-[5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene]amino]oxyethanamine; 2-[({5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene}amino)oxy]ethanamine; Dumirox; Dumyrox; Faverin; Floxyfral; Fluvoxamina; Fluvoxamina [INN-Spanish]; Fluvoxamine (INN); Fluvoxamine [INN:BAN]; Fluvoxamine-CR; Fluvoxaminum; Fluvoxaminum [INN-Latin]; Luvox (TN); Maveral
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Obsessive compulsive disorder [ICD11: 6B20] | Approved | [1] | |||
| Therapeutic Class |
Antidepressants
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C15H21F3N2O2
|
|||||
| Canonical SMILES |
COCCCCC(=NOCCN)C1=CC=C(C=C1)C(F)(F)F
|
|||||
| InChI |
InChI=1S/C15H21F3N2O2/c1-21-10-3-2-4-14(20-22-11-9-19)12-5-7-13(8-6-12)15(16,17)18/h5-8H,2-4,9-11,19H2,1H3/b20-14+
|
|||||
| InChIKey |
CJOFXWAVKWHTFT-XSFVSMFZSA-N
|
|||||
| CAS Number |
CAS 54739-18-3
|
|||||
| Pharmaceutical Properties | Molecular Weight | 318.33 | Topological Polar Surface Area | 56.8 | ||
| Heavy Atom Count | 22 | Rotatable Bond Count | 9 | |||
| Hydrogen Bond Donor Count | 1 | Hydrogen Bond Acceptor Count | 7 | |||
| XLogP |
2.6
|
|||||
| PubChem CID | ||||||
| PubChem SID |
103112227
, 103214033
, 103937470
, 114182507
, 11571264
, 117504588
, 124749760
, 124883444
, 124883445
, 124883446
, 126628425
, 126651435
, 126666543
, 131318468
, 134338027
, 134339778
, 135004455
, 137002947
, 139157656
, 143472592
, 144204388
, 14899201
, 160963524
, 162182990
, 163392547
, 163842794
, 164841793
, 164841794
, 17425133
, 26751469
, 39297346
, 47276707
, 47350437
, 47425375
, 48020069
, 48020070
, 49699379
, 50002999
, 50103976
, 51005940
, 57361188
, 7979296
, 85788587
, 90340960
, 92718857
, 93166767
, 93310594
, 96024678
, 9774
, 99373241
|
|||||
| ChEBI ID |
ChEBI:5138
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [2] | |
| References | ||||||
| 1 | Fluvoxamine was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds--implications for pharmacokinetics of selected substrates. J Pharm Pharmacol. 2004 Aug;56(8):967-75. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.